Proxy Results Form 8 K

Item 5.07 Submission of Matters to a Vote of Security Holders.

On October 25, 2024, Qualigen Therapeutics, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") to consider the proposals described in the Company's definitive proxy statement and supplement filed with the Securities and Exchange Commission on September 10, 2024 and October 9, 2024 (the "Proxy Statement"). The final results for each of the matters voted on at the Annual Meeting were as follows:

1. Election of the Director Nominees:

		Votes For		Votes Against		Votes Withheld		Broker Non-Votes
Robert Lim		14,657,957		0		270,500		2,680,191
Campbell Becher		14,637,828		0		290,629		2,680,191
Cody Price		14,673,820		0		254,637		2,680,191
Kevin A. Richardson, II		14,306,565		0		621,892		2,680,191
Braeden Lichti		14,309,821		0		618,636		2,680,191

Each director nominee was elected to serve as a director until the Company's annual meeting of stockholders in 2025, or until such person's successor is duly elected and qualified or until such person's earlier resignation, death, or removal.

2. Proposal to ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December 31, 2024:

Votes For		Votes Against		Votes Abstaining
17,030,627		546,005		32,016

The proposal was approved.

3. Proposal to approve an amendment to our amended and restated certificate of incorporation, as amended, to effect a reverse stock split of our outstanding shares of common stock at a reverse stock split ratio ranging from 10:1 to 50:1, inclusive, as determined by the board of directors;

Votes For		Votes Against		Votes Abstaining
16,165,754		1,435,884		7,010

The proposal was approved.

4. Proposal to approve the adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies:

Votes For		Votes Against		Votes Abstaining
16,196,305		1,391,572		20,771

The proposal was approved.

5. Proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance to Alpha Capital Anstalt ("Alpha") of more than 20% of the Company's issued and outstanding common stock pursuant to the terms and conditions of (a) the 8% Senior Convertible Debenture Due December 22, 2025 in favor of Alpha, and (b) the Company's common stock purchase warrant dated December 22, 2022 issued to Alpha:

Votes For		Votes Against		Votes Abstaining		Broker Non-Votes
14,562,299		347,563		18,595		2,680,191

The proposal was approved.

6. Proposal to approve, on a non-binding, advisory basis, the compensation of our named executive officers:

Votes For		Votes Against		Votes Abstaining		Broker Non-Votes
14,540,812		297,422		90,223		2,680,191

The proposal was approved.

Public link

Please use the above public link if you want to share this noodl on another website.